NBCn1 is known for its vital role in shuttling bicarbonate ions in concert with sodium ions across cellular membranes, effectively modulating intracellular pH. Its function influences numerous cellular activities such as metabolism, signal transduction, and ion channel regulation. Despite its importance, high-resolution structural information about NBCn1 has remained elusive, hindering the development of targeted therapies for conditions linked to dysfunctional pH regulation, including cancer, neurological disorders, and renal pathologies. This pioneering research fills that critical knowledge gap by revealing the transporter’s conformational landscapes and gating mechanisms at near-atomic detail.

The investigators employed CryoEM, a revolutionary technique capable of visualizing biomolecules in their native states without the need for crystallization, enabling the capture of NBCn1 crystal-clear images while immersed in a solution that mimics physiological conditions. By freezing the transporter swiftly in vitreous ice, the team preserved its functional conformations. The integration of computational modeling then allowed the refinement of structural data to manage regions less defined by raw microscopy, producing a complete and precise topological map of NBCn1’s membrane-embedded domains.

The elucidated structure highlights distinct features responsible for ion coordination and translocation. Notably, the study identifies a unique ion binding pocket formed by conserved amino acid residues meticulously arranged to facilitate the selective passage of bicarbonate while simultaneously co-transporting sodium ions. This dual-ion specificity is crucial for maintaining electroneutral transport, ensuring that the movement of ions across the membrane does not disrupt membrane potential – a fundamental principle for cellular homeostasis.

Moreover, the research delves into the dynamic conformational shifts NBCn1 undergoes to alternate between inward-facing and outward-facing states, a hallmark of secondary active transporters operating via an alternating access mechanism. The high-resolution snapshots depict a well-orchestrated series of domain movements, underscoring how the protein gates open and close cyclically to prevent ion backflow, thereby sustaining directional bicarbonate and sodium flux. These conformational insights offer a clearer understanding of how NBCn1 activity can be modulated allosterically or via post-translational modifications.

Intriguingly, the study also reveals a notable pH-sensitive regulatory motif embedded within the transporter’s architecture. This motif functions as an intrinsic sensor that influences NBCn1’s activity in response to shifts in the cellular or extracellular proton concentration, fine-tuning the transporter’s efficiency based on environmental cues. Deciphering this regulatory mechanism sheds light on the molecular basis of pH-dependent modulation, a feature that may prove critical in designing pharmaceutical agents that selectively alter NBCn1 function under pathological conditions.

This work stands out not only due to its technical prowess but also owing to the comprehensive computational simulations that complement the experimental data. Using molecular dynamics, the research team simulated the transport cycle over extended timescales, capturing transient intermediate states that evade experimental detection. These simulations helped contextualize experimental observations within a dynamic framework, increasingly essential for understanding membrane protein functions that transcend static snapshots.

The biomedical implications of these findings are immense. NBCn1 has been implicated in cancer cell proliferation and migration, where altered pH regulation confers a survival advantage in tumor microenvironments. By providing a structural blueprint, this study propels the development of custom-designed inhibitors or modulators that can specifically target NBCn1’s ion-binding or regulatory sites, potentially attenuating cancer progression. Furthermore, aberrations in NBCn1 function have been associated with neurological diseases characterized by dysregulated ion transport, suggesting broader clinical applications.

In addition to human health, the structural insights into NBCn1 extend to fundamental physiology. The transporter’s role in maintaining systemic acid-base balance was always acknowledged, but now, mechanistic details clarify how NBCn1 integrates with other ionic transporters to sustain cellular environments conducive to optimal enzyme activity and metabolic flux. Understanding these interactions on a molecular level also presents opportunities to investigate compensatory mechanisms that cells activate in response to NBCn1 dysfunction.

This seminal research exemplifies the symbiotic power of CryoEM and computational biology in membrane protein research. Historically challenging due to their hydrophobic nature and dynamic conformations, membrane proteins like NBCn1 are now accessible to atomic-level scrutiny. The methodologies employed here could be extrapolated to other SLC4 family members, facilitating comparative analyses that might unravel evolutionary conserved mechanisms or specialization tailored to distinct physiological niches.

Looking forward, the study invites further exploration into NBCn1’s interaction with cellular partners. Proteins rarely act in isolation, and NBCn1’s association with scaffolding proteins, kinases, or regulatory factors likely modulates its function within complex cellular milieus. Integrative structural biology approaches, such as CryoEM coupled with cross-linking mass spectrometry and live-cell imaging, could provide a holistic view of NBCn1 within its native interactome and functional assemblies.

Beyond the basic science, translational prospects loom large. The discoveries equip pharmaceutical developers with tangible structural templates for rational drug design campaigns, possibly enabling high-throughput screens of small molecules that bind unique conformational states of NBCn1. This approach heralds a new era of precision medicine targeting ion transporters previously deemed undruggable due to structural and dynamic complexity.

In conclusion, this research delivers a tour de force in molecular medicine by demystifying the structural basis of NBCn1’s pH regulating capabilities. As both a physiological cornerstone and a potential therapeutic target, understanding the detailed workings of NBCn1 furnishes the scientific community with a critical foundation to exploit for future health innovations. With advances like this, the once enigmatic landscape of membrane transporter biology is rapidly transforming, promising novel interventions against diseases rooted in fundamental ionic dysregulation.

Subject of Research: Structural and functional characterization of the pH regulator NBCn1 (sodium bicarbonate cotransporter) through CryoEM and computational modeling.

Article Title: CryoEM and computational modeling structural insights into the pH regulator NBCn1.

Article References:
Wang, W., R. Zhekova, H., Tsirulnikov, K. et al. CryoEM and computational modeling structural insights into the pH regulator NBCn1. Nat Commun 16, 9932 (2025). https://doi.org/10.1038/s41467-025-64868-z

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-025-64868-z

In recent years, secreted proteins have emerged as key players in the pathogenesis and potential treatment of MASLD. These proteins, secreted into the extracellular space, engage in complex autocrine, paracrine, and endocrine signaling to modulate cellular metabolism, inflammation, and tissue remodeling. Their multifaceted roles offer unique opportunities to intervene at various stages of MASLD progression, ranging from lipid accumulation to fibrotic remodeling. Current research efforts focus on elucidating the mechanistic pathways these proteins engage, aiming to exploit their signaling properties therapeutically.

Among the myriad secreted proteins implicated in MASLD, the orosomucoid (ORM) family, especially ORM1, has captured considerable attention. ORM1 expression in extrahepatic tissues appears to mediate systemic metabolic regulation, offering hepatoprotective effects by mitigating steatosis and inflammation. Dysregulation of ORM1 correlates strongly with metabolic derangements and liver injury in MASLD, suggesting that targeted modulation of this protein could recalibrate metabolic homeostasis and decrease disease severity. This concept opens avenues for novel ORM-based therapeutics designed to harness its regulatory effects.

Matricellular proteins such as secreted protein acidic and rich in cysteine (SPARC) are also central to fibrogenesis and inflammation in MASLD. Elevated SPARC expression is consistently linked with enhanced extracellular matrix deposition and inflammatory signaling within the hepatic microenvironment, accelerating fibrosis and functional deterioration. Intervening in SPARC-mediated pathways may thus curb the fibrotic cascade, presenting a promising target for halting or reversing disease progression in advanced MASLD stages.

Another pivotal class of secreted proteins relevant to MASLD is the neuregulin (Nrg) family. Neuregulin 4 (Nrg4), an adipokine released predominantly by brown adipose tissue, exerts profound protective effects against hepatic steatosis and inflammatory infiltration. Mechanistically, Nrg4 dampens de novo lipogenesis and stimulates the ErbB4/AKT signaling axis, orchestrating metabolic reprogramming within hepatocytes that favors lipid clearance and anti-inflammatory states. The therapeutic efficacy of Nrg4 analogs is currently under active exploration, as their modulation may attenuate disease progression and improve liver function.

Growth differentiation factors (GDFs), notably GDF15 and GDF10, contribute to hepatic metabolic regulation by inhibiting lipogenesis and enhancing oxidative metabolism. Their expression and secretion are tightly regulated under metabolic stress, and experimental models reveal their capacity to protect against lipid-induced liver injury. Although the translational leap from preclinical findings to clinical application remains complex, GDFs represent attractive molecular targets with hepatoprotective promise grounded in their dual metabolic and anti-inflammatory capabilities.

Integral to the immune-metabolic interface, interleukin-22 (IL-22) has garnered considerable attention for its multi-modal hepatoprotective functions. IL-22 modulates inflammatory cascades, reduces hepatocyte lipid burden, and impedes fibrotic signaling pathways, positioning it as a powerful biological agent against MASLD and metabolic dysfunction-associated steatohepatitis (MASH). Clinical trials employing recombinant IL-22 analogs report encouraging outcomes, highlighting reduced hepatic steatosis and fibrosis markers, which advocates for further development of IL-22-based interventions.

Parallel to cytokine modalities, fibroblast growth factors (FGFs)—especially FGF21 and engineered analogs of FGF19—demonstrate significant metabolic benefits in MASLD patient cohorts. These factors act pleiotropically, orchestrating lipid metabolism, glucose homeostasis, and energy expenditure through receptor-mediated signaling cascades. Clinical trials have showcased their ability to reduce hepatic fat content and fibrotic progression, affirming their therapeutic value and informing the design of next-generation biotherapeutics to combat metabolic liver diseases.

Bone morphogenic proteins (BMPs) add yet another layer of complexity to MASLD pathobiology. BMP4, BMP6, and BMP7 exhibit protective properties by modulating lipid metabolism and inflammatory processes, offering anti-fibrotic benefits. Conversely, BMP8B and BMP9 demonstrate more ambiguous roles, sometimes exacerbating disease phenotypes. Clarifying these divergent effects is paramount for fully harnessing BMP signaling in the clinical management of MASLD, necessitating deeper mechanistic studies and translational research.

Emerging actors such as Isthmin-1 (Ism1) and mesencephalic astrocyte-derived neurotrophic factor (MANF) enhance our understanding of the intricate metabolic networks influencing MASLD progression. Ism1 promotes adipocyte glucose uptake and inhibits hepatic lipid synthesis, effectively rebuffing steatotic changes. MANF, through its endoplasmic reticulum stress-modulating properties, suppresses lipogenesis and attenuates fibrogenesis, indicating promising roles as therapeutic adjuncts or synergistic agents in treatment regimens aimed at metabolic and fibrotic sequelae.

The promise of secreted protein-based therapies in MASLD is not without challenges. Translational hurdles include optimizing dosage to maximize beneficial hepatic and extrahepatic effects while minimizing adverse outcomes, addressing the heterogeneity of patient phenotypes, and overcoming limitations intrinsic to current animal models that insufficiently recapitulate human disease complexity. Innovative bioengineering approaches, including protein engineering and targeted delivery systems, are being actively pursued to overcome these barriers.

Future directions pivot on integrating molecular insights with clinical realities to establish secreted proteins as viable therapeutic agents. Precision medicine approaches that stratify MASLD patients based on molecular and metabolic profiles will improve therapeutic outcomes by tailoring interventions. Furthermore, multi-omics technologies and advanced in vitro models, such as organoids and humanized liver systems, are accelerating the discovery pipeline, ensuring that candidate secreted proteins possess both mechanistic validity and translational relevance.

The comprehensive review titled “Exploring Secreted Proteins as Therapeutic Targets for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)” published in Protein & Cell on April 17, 2025, epitomizes this new frontier in hepatic research. It collates experimental insights surrounding secreted proteins and underscores their multifaceted roles in MASLD pathophysiology. By bridging bench findings and clinical prospects, this body of work charts a path toward novel biological therapies that could transform the therapeutic landscape for millions suffering from metabolic liver diseases.

The evolving understanding of secreted proteins underscores a paradigm shift from symptom management to targeted molecular therapy. Their ability to influence diverse biological processes integral to MASLD—from lipid metabolism and inflammation to fibrogenesis—positions them at the forefront of innovative treatment development. Continued multidisciplinary collaboration between basic scientists, clinicians, and pharmacologists will be essential to translate these promising candidates into effective, safe, and personalized therapies.

In summary, secreted proteins offer a vibrant and promising frontier for therapeutic innovation in MASLD. By harnessing their intrinsic signaling capacities, modulating metabolic dysfunction becomes a feasible goal, offering hope for an otherwise difficult-to-treat condition. The future of MASLD treatment lies in these molecular emissaries as we inch closer to a precision medicine era, transforming care paradigms and improving lives.

Subject of Research: Not applicable
Article Title: Secreted proteins in treating metabolic dysfunction-associated steatotic liver disease: from bench towards bedside
News Publication Date: April 17, 2025
Web References: http://dx.doi.org/10.1093/procel/pwaf027
Image Credits: Yeping Huang, Bin Liu, Cheng Hu, Yan Lu
Keywords: Cells